These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22451466)

  • 1. [Development of unapproved drugs-- current status in Japan].
    Yoshino T
    Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):113-6. PubMed ID: 22451466
    [No Abstract]   [Full Text] [Related]  

  • 2. Delays in neurological drug development in Japan.
    Shimazawa R; Ikeda M
    Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personal imports of drugs to Japan in 2005--an analysis of import certificates.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2008 Oct; 33(5):545-52. PubMed ID: 18834370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unapproved drugs--the drug information pharmacists' perspective.
    Giouroukakis M; Dryer M
    J Pharm Pract; 2013 Apr; 26(2):112-9. PubMed ID: 23459285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs.
    Hakim A; Gupta R; Ross JS
    JAMA; 2017 Dec; 318(22):2181-2182. PubMed ID: 29131905
    [No Abstract]   [Full Text] [Related]  

  • 8. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
    Ostroff C; Lee CE; McMeekin J
    Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan.
    Asada R; Shimizu S; Ono S; Ito T; Shimizu A; Yamaguchi T
    J Clin Pharm Ther; 2013 Aug; 38(4):309-13. PubMed ID: 23574352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of drug-approval regulations for medical countermeasures against CBRN agents in Japan.
    Shimazawa R; Ikeda M
    Health Secur; 2015; 13(2):130-8. PubMed ID: 25813978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug development in Japan from the viewpoints of global pharmaceutical companies].
    Seriu T
    Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse events of unapproved drugs in Japan.
    Miyakoshi S; Kusumi E; Kodama Y; Narimatsu H; Hamaki T; Matsumura T; Kami M
    Lancet Oncol; 2008 May; 9(5):414-5. PubMed ID: 18452854
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan.
    Nishiwaki S; Ando Y
    J Glob Oncol; 2019 Nov; 5():1-3. PubMed ID: 31702945
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
    Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
    Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Challenges and prospects for drug development of molecular targeting agents in Japan].
    Iwasaki M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():695-702. PubMed ID: 23513923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.